Mission

The objective of PARCIVAL is to develop an integrated and automated multi-analyte lab-on-a-disk platform for the fast and reliable sample in-answer out diagnosis of highly infectious respiratory pathogens, resistance patterns, and biomarkers for individual severity of the infection. The platform format will be based on completely integrated microfluidic foil-disposables. The disposables will feature different panels (selection of pathogens, resistance patterns, biomarkers), which can be freely selected and combined to allow a comprehensive choice of diagnostic parameters by the clinician at the point-of-care, vastly increasing the access to diagnostic information for doctors in everyday situations and emergencies. The integrated platform with pre-packaged liquid and dry reagents will automate all processing steps from sample preparation to assay processing to result reporting. This will allow evidence-based therapeutic decisions and allow antibiotic prescriptions that are tailored to the individual patient and thus offer the prospect to greatly improve therapeutic outcomes. Also, an air-sampling add-on module for monitoring of clinical ventilation systems will be developed and interfaced to the platform.

Consortium History

The project started on Jan. 1 2012, and lasted for three years.

Structure & Governance

The consortium consists of nine partners (six enterprises, four of which are SMEs, and three institutes).

Sponsors & Partners

PARCIVAL is a project financed by the EC (FP7-HEALTH Collaborative project).

e-mail: info@parcival-project.eu